TC
EGRX

TFS Capital’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

TFS Capital’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-34,860
Closed -$2.82M – 1065
2015
Q2 		$2.82M Buy
34,860
+12,108
+53% +$789K 0.28% 86
2015
Q1 		$953K Buy
+22,752
New +$645K 0.09% 363

Other funds holding EGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
GE
General Electric Evendale, Ohio $369M AUM 19.65% 1-Year Est. Return

TFS Capital's EGRX Position: Q3 2015 in Review

TFS Capital sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2015, closing a stake of 34,860 shares — an estimated $2.82M sold.

TFS Capital first reported a position in EGRX in Q1 2015 and held it in 2 quarters. The position peaked at $2.82M in Q2 2015. 119 funds tracked by Wall St. Rank hold EGRX as of Q3 2015.

  • TFS Capital reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • TFS Capital sold 34,860 Eagle Pharmaceuticals, Inc. shares in Q3 2015, an estimated $2.82M.
  • TFS Capital first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and held it in 2 quarters.
  • TFS Capital's Eagle Pharmaceuticals, Inc. position peaked at $2.82M in Q2 2015.
  • 119 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2015.

Based on TFS Capital's 13F filing for Q3 2015, filed 3 Nov 2015.